Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nevirapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nevirapine SCHEMBL30267890 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL29614675 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL29393780 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL3232525 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL6562884 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL5175341 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL1923903 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL8151939 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| SCHEMBL9704195 | 0.95 | ALDH1A1 (0.91) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL28679264 | 0.94 | ALDH1A1 (0.89) | ALDH1A1LMNAPOLBADORA3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 39931 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| WO-2026107113-A1 | MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF | CALIDI BIOTHERAPEUTICS (NEVADA), INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260124290-A1 | HIV Immunogens, Vaccines, and Methods Related Thereto | UNIV EMORY (US) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4735033-A2 | MRNA-ENCODED TAT WITH ATTENUATED CYTOTOXICITY FOR HIV AND SIV LATENCY REVERSAL | The Trustees of the University of Pennsylvania (US) | 2026-05-06 | — | — | EP | claimed |
| WO-2026085583-A1 | MOLECULAR ASSAY FOR DETECTING HIV-1 DRUG-RESISTANT MUTATIONS | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2026-04-30 | — | — | WO | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | claimed |
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | GILEAD SCIENCES, INC. (US) | 2026-04-28 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| WO-1995016688-A1 | HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 1995-06-22 | — | — | WO | claimed |
| EP-0633887-A1 | CALANOLIDE ANTIVIRAL COMPOUNDS, COMPOSITIONS AND USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-01-18 | — | — | EP | claimed |
| US-5366972-A | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1994-11-22 | — | — | US | claimed |
| CN-1094310-A | Combination chemotherapy for HIV infection | THOMAS C MERIGAN (US) | 1994-11-02 | — | — | CN | claimed |
| US-5358721-A | Antiviral therapy | ALZA CORPORATION (US) | 1994-10-25 | — | — | US | claimed |
| WO-1994020519-A1 | COMPOUNDS ACTIVE AGAINST AIDS AND RELATED INFECTIONS | PURDUE RESEARCH FOUNDATION (US) | 1994-09-15 | — | — | WO | claimed |
| WO-1994017055-A1 | ANTIVIRAL NAPHTHOQUINONE COMPOUNDS, COMPOSITIONS AND USES THEREOF | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-08-04 | — | — | WO | claimed |
| WO-1994013314-A1 | COMBINATION FOR TREATING HIV INFECTIONS CONTAINING THYMOSINE, INTERLEUKIN AND HIV REPLICATION OR REVERSE TRANSCRIPTASE INHIBITORS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1994-06-23 | — | — | WO | claimed |
| WO-1993020082-A1 | CALANOLIDE ANTIVIRAL COMPOUNDS, COMPOSITIONS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-10-14 | — | — | WO | claimed |
| EP-0429987-A2 | 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1991-06-05 | — | — | EP | claimed |